To the Editor:Diffuse large B-cell lymphoma(DLBCL)exhibits clinical significance and biological diversity.Over the last two decades,rituximab with cyclophosphamide,doxorubicin,vincristine,and prednisone(R-CHOP)has substantially improved outcomes for DLBCL patients.However,approximately one-third of DLBCL cases continue to experience disease progression,resulting in long-term survival ranging from 50%to 60%.[1]Efforts to improve DLBCL patient outcomes by modifying R-CHOP dosing schedules have yielded limited success,and the addition of new drugs has benefited only specific patient subgroups.Nevertheless,intensive immunochemotherapy(IIC)has demonstrated promise and cost-effectiveness in recent years.The regimen of dose-adjusted etoposide.
Hesong Zou;Wei Liu;Yi Wang;Dandan Shan;Ting Xie;Ru Li;Huimin Liu;Wenyang Huang;Mingwei Fu;Tingyu Wang;Rui Lyu;Shuhui Deng;Weiwei Sui;Yan Xu;Shuhua Yi;Gang An;Lugui Qiu;Dehui Zou;
State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Science&Peking Union Medical College,Tianjin 300020,ChinaTianjin Institutes of Health Science,Tianjin 301600,ChinaState Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Science&Peking Union Medical College,Tianjin 300020,China Tianjin Institutes of Health Science,Tianjin 301600,China
临床医学
CHOP;drugs;chemotherapy;
《Chinese Medical Journal》 2024 (013)
P.1620-1622 / 3
CAMS Innovation Fund for Medical Sciences(Nos.CIFMS 2022-I2M-1-022 and 2020-I2M-C&T-B-085)
10.1097/CM9.0000000000002940
评论